DEA Developing Pain Drug Prescribing Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency is soliciting comments for document intended to “reiterate legal concepts.” New principles will not be outlined, but DEA is hoping to create a “single, comprehensive document” after withdrawing a list of frequently asked questions because of “misstatements.”
You may also be interested in...
Sepracor Lunesta Launch Delayed By Controlled Substance Scheduling
Sepracor plans for Lunesta to be available within the first quarter of 2005 after the completion of formal Drug Enforcement Agency classification of eszopiclone as a Schedule IV substance. The company originally planned to launch the insomnia agent in early January following FDA approval in December.
Elan Prialt Clears FDA, Will Launch In Late January
Intrathecal therapy is indicated for "the management of severe chronic pain in patients…who are intolerant or refractory to other treatment." Elan will promote the non-opioid therapy with 40 to 50 sales reps targeting 3,000 doctors.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.